This may partially explain why our findings differ from those of a previous meta-analysis4 which did not find a significant difference in blood GFAP levels between AD and CU populations, based on meta-analysis of 3 anti-GFAP autoantibody studies, 1 study reporting on GFAP levels from astrocyte-derived exosomes, and only 1 study that directly reported blood GFAP levels. The gene discussed is GFAP; the disease is Alzheimer disease.